Clinical Trials Logo

Clinical Trial Summary

Although hepatitis C virus (HCV) infection remains one of the main causes of hepatocellular carcinoma (HCC) worldwide, metabolic syndrome, with its increase in prevalence, has become an important and significant risk factor for HCC


Clinical Trial Description

Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide. In Egypt, it represents the fourth common cancer. Many hospital-based studies reported increasing the incidence of HCC. The reason for increased incidence could be attributed to (1) improvement in screening programs and diagnostic tools, (2) increasing the survival rate of cirrhotic patients that increases the chance of developing HCC, and (3) increasing the incidence and complications of hepatitis C virus (HCV) which is the most important risk factor in developing liver cancer including HCC in Egypt Precise staging of HCC initially is very useful for determination of the therapeutic options and the overall prognosis of the disease. There are certain clinical features upon which most staging systems use for HCC assessment. These clinical features are size and local extent of the tumor, metastasis of the tumor, severity of the liver disease, and the overall patient performance status Several studies in the United States, Europe, Taiwan, Hong Kong , and New Zealand have examined the potential relationships between various metabolic factors and HCC risks, mostly focusing on type 2 DM and obesity. Diabetes , or even prediabetes, has been observed to be a major metabolic factor related to an increased risk of HCC in individuals with HBV infections. There is paucity in literature about effect of metabolic syndrome on Long-term Survival Following Liver Resection for Hepatocellular Carcinoma Among Patients With Chronic Hepatitis C Virus Infection ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05568576
Study type Observational
Source Assiut University
Contact
Status Completed
Phase
Start date January 1, 2015
Completion date December 30, 2022

See also
  Status Clinical Trial Phase
Completed NCT01952184 - Oocyte Survival After Vitrification in an Open or Closed Device With Closed Storage. N/A
Completed NCT00993343 - Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation Phase 3
Recruiting NCT04808466 - Comparative Study of Lobaplatin and Paclitaxel in Advanced Gastric Cancer Patients With D2 Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Not yet recruiting NCT04845490 - Comparative Study of Mitomycin and Lobaplatin in Advanced Colorectal Cancer Patients With Radical Surgery Combined With Hyperthermic Intraperitoneal Chemotherapy Phase 2
Recruiting NCT03291275 - Survival Outcomes of Uterine Malignancies in Chinese Population N/A
Recruiting NCT05720858 - Telerehabilitation in Survival Breast Cancer Patients N/A
Completed NCT03351920 - Ventilation's Parameters Applied in Emergency Medicine. A Prospective Observational Study
Not yet recruiting NCT06147180 - Comparison of Long-term Survival and Quality of Life After Minimally Invasive Esophagectomy Versus Open Esophagectomy
Recruiting NCT04472403 - Platinum Plus Low-dose Long-term Continuous Intravenous Infused 5-Fluorouracil in Metastatic Nasopharyngeal Carcinoma
Recruiting NCT03739944 - Different Surgical Approaches in Patients of Early-stage Cervical Cancer Phase 3
Not yet recruiting NCT02960061 - Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer Phase 3
Recruiting NCT03738969 - Longitudinal Study of Different Surgical Approaches in Chinese Patients of Uterine Cervical Cancer
Completed NCT03134807 - The Very Old Intensive Care Patient: A Multinational Prospective Observation Study
Completed NCT03084809 - Chemotherapy Combined With CIK Treating Colon Cancer Phase 4
Completed NCT03642041 - Study of Smoking Trajectory in Newly Diagnosis Lung Cancer Patients
Recruiting NCT04351308 - Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma Phase 2
Recruiting NCT03920033 - Salvage Hypofractionated Accelerated Versus Standard Radiotherapy for Biochemical Failure After Prostatectomy N/A
Recruiting NCT05540119 - Swedish Oesophago-Gastric Study
Completed NCT04519450 - Ultrasound of Accessory Respiratory Muscles
Active, not recruiting NCT01835821 - Clinical Study of Porcelain-fused and IPS e.Max CAD Crowns N/A